Summary
Global
Markets Direct's, 'Kancera AB - Product Pipeline Review - 2016', provides an
overview of the Kancera AB's pharmaceutical research and development focus.
The
report provides comprehensive information on the therapeutics under development
by Kancera AB, complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and the dormant and discontinued
projects.
Browse Ongoing
Reports @ http://www.radiantinsights.com/research/kancera-ab-product-pipeline-review-2016
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Note*: Certain
sections in the report may be removed or altered based on the availability and
relevance of data.
Buy a Sample Copy
of This Report @ http://www.radiantinsights.com/research/kancera-ab-product-pipeline-review-2016/request-sample
No comments:
Post a Comment